Navigation Links
Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
Date:1/31/2012

or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the Data Safety Monitoring Board's recent determination disclosed in our Form 8-K dated September 15, 2011 recommending that Soligenix stop its confirmatory Phase 3 clinical trial of orBec® in acute GI GVHD and the likelihood that: the FDA will  require that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® which will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201, SGX202, SGX203, SGX204, RiVax™ and LPMTM are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

 


'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
10. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
11. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative ... information about dual arch impressions on its dental blog. ... the blog entry serves up a list of tips to ... demonstration by Dr. David Little as he crafts a porcelain ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... life sciences industry faces a host of policy ... and nationally, SAN FRANCISCO, Jan. 10 ... providing a broad overview of,the productivity of Northern ... science research cluster in the world. To ensure,continued ...
... France, January 10 Transgene,(Euronext Paris: FR0005175080) announces ... its therapeutic vaccine TG4010,(MVA-MUC1-IL2) as an adjunct to ... lung cancer (NSCLC)., This on-going trial is ... assess the efficacy of TG4010 in combination with ...
... BIRMINGHAM, Alabama,Jan. 10 CANTOX HEALTH SCIENCES INC. ... regulatory consulting firm with,specialized expertise in the areas ... Agriculture, Biotech & Consumer Products announces,the launch of ... their,Pharmaceutical & Healthcare Division., For the past ...
Cached Biology Technology:Bioscience Group Warns Policymakers Against Complacency 2Bioscience Group Warns Policymakers Against Complacency 3Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division 2
(Date:4/17/2014)... researchers have detected new early-warning signs of the potential ... have far-reaching implications for the diagnosis and treatment of ... million Americans. , "We had not expected to see ... stages," said Ann Elsner, professor and associate dean in ... the study. "We set out to study the early ...
(Date:4/17/2014)... full of wild animals and plant life, but there,s ... churning away in the soil, decomposing organic matter and ... role these fungi play in ecological systems, their identities ... scientists has generated a genetic map of more than ... was published this week in the Proceedings of ...
(Date:4/17/2014)... Modern View of Domestication," a special feature of ... Sciences ( PNAS ) published April 29, raises ... our deep history that most of us take for ... people in many spots around the globe shifted from ... livestock and plants. , It seems so straightforward and ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... This release is available in German . , ... but also many adults get uneasy when they hear those words ... skin the piercing pain can be felt very clearly. "After such ... the next vaccination appointment to activate our pain memory", knows Prof. ...
... order for a gene to create a protein, the gene,s ... RNA. These RNA molecules are the instruction manuals that show ... build a protein. A few years ago, scientists studying bacterial ... (metabolites) can bind to. In doing so, they induce the ...
... is exploring the use of Chinese wolfberries to improve vision ... Lin, K-State research assistant professor of human nutrition, is studying ... His findings show that the fruit can lower the oxidative ... diabetes. "I would not say that wolfberries are a ...
Cached Biology News:Do words hurt? 2Genes under control 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 3
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Intestinal Epithelium Differentiation Environment...
... Anti-phospho-Hck [pTyr 209/ pSer 211 ] ... solution in Dulbecco's phosphate buffered saline (without Mg ... with 1.0 mg/ml BSA (IgG and protease free) ... derived from the region of mouse Hck that ...
... provides a familiar interface for data ... warehousing. The transition from paper to ... LABTrack contains an integrated LIMS, ... rules mechanism. These functions allow LABTrack ...
Biology Products: